Insight Molecular Diagnostics (STU:7OC0) E10: €-5.69 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:7OC0 Insight Molecular Diagnostics Inc STU:7OC0
49 GF Score
Price €3.34
GF Value €0.81
! 7 Warning Signs
View Full Analysis

What is Insight Molecular Diagnostics E10?

Insight Molecular Diagnostics STU:7OC0 49 E10 is €-5.69 as of Jun. 2026. GuruFocus rates STU:7OC0 with a GF Score™ of 49/100 and a GF Value™ of €0.81. The stock has 7 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Insight Molecular Diagnostics's adjusted earnings per share data for the three months ended in Jun. 2026 was €-0.269. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €-5.69 for the trailing ten years ended in Jun. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2026-08-26), Insight Molecular Diagnostics's current stock price is €3.34. Insight Molecular Diagnostics's E10 for the quarter that ended in Jun. 2026 was €-5.69. Insight Molecular Diagnostics's Shiller PE Ratio of today is .


Insight Molecular Diagnostics  (STU:7OC0) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Insight Molecular Diagnostics E10 Related Terms


Insight Molecular Diagnostics E10 Historical Data

* Premium members only.

The historical data trend for Insight Molecular Diagnostics's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Insight Molecular Diagnostics E10 Chart

Insight Molecular Diagnostics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 -16.34 -4.59

Insight Molecular Diagnostics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -11.93 -10.70 -4.59 -10.37 -5.69

STU:7OC0 vs XGN, BNR, BDSX: E10 Comparison

For the Diagnostics & Research subindustry, Insight Molecular Diagnostics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Insight Molecular Diagnostics Shiller PE Ratio vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Insight Molecular Diagnostics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Insight Molecular Diagnostics's Shiller PE Ratio falls into.


STU:7OC0
49GF Score
Insight Molecular Diagnostics Inc STU:7OC0
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Insight Molecular Diagnostics E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Insight Molecular Diagnostics's adjusted earnings per share data for the three months ended in Jun. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=-0.269/333.9520*333.9520
=-0.269

Current CPI (Jun. 2026) = 333.9520.

Insight Molecular Diagnostics Quarterly Data

per share eps CPI Adj_EPS
201609 -1.782 241.428 -2.465
201612 -2.086 241.432 -2.885
201703 -2.992 243.801 -4.098
201706 -2.314 244.955 -3.155
201709 -3.692 246.819 -4.995
201712 -2.197 246.524 -2.976
201803 -1.946 249.554 -2.604
201806 -2.054 251.989 -2.722
201809 -1.200 252.439 -1.587
201812 -1.934 251.233 -2.571
201903 -1.416 254.202 -1.860
201906 -1.833 256.143 -2.390
201909 -1.816 256.759 -2.362
201912 -2.700 256.974 -3.509
202003 -2.353 258.115 -3.044
202006 -2.486 257.797 -3.220
202009 -1.698 260.280 -2.179
202012 -1.480 260.474 -1.897
202103 -0.840 264.877 -1.059
202106 -1.992 271.696 -2.448
202109 -2.550 274.310 -3.104
202112 -6.903 278.802 -8.268
202203 -1.998 287.504 -2.321
202206 -1.400 296.311 -1.578
202209 -1.636 296.808 -1.841
202212 -7.580 296.797 -8.529
202303 0.374 301.836 0.414
202306 -0.988 305.109 -1.081
202309 -0.759 307.789 -0.824
202312 -1.898 306.746 -2.066
202403 -1.040 312.332 -1.112
202406 -0.334 314.175 -0.355
202409 -0.883 315.301 -0.935
202412 -1.843 315.605 -1.950
202503 -0.240 319.799 -0.251
202506 -0.260 322.561 -0.269
202509 -0.290 324.800 -0.298
202512 -0.615 324.054 -0.634
202603 -0.104 330.213 -0.105
202606 -0.269 333.952 -0.269

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of €-5.69 mean?
Insight Molecular Diagnostics (STU:7OC0) has a E10 of €-5.69 as of Jun. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Insight Molecular Diagnostics and its competitors.
Is Insight Molecular Diagnostics' E10 too high?
Insight Molecular Diagnostics' current E10 is €-5.69. Overall, Insight Molecular Diagnostics has a GF Score™ of 49/100, reflecting its overall financial health beyond just this single metric.
How does Insight Molecular Diagnostics' E10 compare to XGN and BNR?
Insight Molecular Diagnostics' E10 of €-5.69 can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Medical Diagnostics & Research company?
A good E10 depends on the Medical Diagnostics & Research industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Insight Molecular Diagnostics and its competitors. Insight Molecular Diagnostics's current E10 is €-5.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Insight Molecular Diagnostics stock overvalued right now?
Insight Molecular Diagnostics (STU:7OC0) has a current E10 of €-5.69. The stock's GF Value™ is €0.81, compared to a current price of €3.34 — trading 312.3% above its estimated fair value. The current E10 is €-5.69. Insight Molecular Diagnostics' overall GF Score™ is 49/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Insight Molecular Diagnostics (STU:7OC0), the current E10 is €-5.69 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Insight Molecular Diagnostics (STU:7OC0) Overvalued in 2026?

Based on GuruFocus' analysis, Insight Molecular Diagnostics stock appears to be overvalued. The current stock price of €3.34 is trading 312.3% above its estimated GF Value™ of €0.81.

Key valuation signals for STU:7OC0:

  • E10: €-5.69
  • GF Value™: €0.81 vs. price of €3.34 (312.3% above fair value)
  • GF Score™: 49/100 with 7 warning signs

No single metric tells the full story. See the STU:7OC0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Insight Molecular Diagnostics Business Description

Other Exchanges IMDX:USA0KCC:UK7OC0:Germany
Address 2 International Plaza Drive, Suite 510, Nashville, TN, USA, 37217
Insight Molecular Diagnostics Inc is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. The Company's flagship technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). It is also in the process of rebranding its RUO test kit, GraftAssure, as GraftAssureIQ, and rebranding its future in-vitro diagnostic (IVD) test kit as GraftAssureDx. The company geographically operates in the United States, the United Kingdom, Europe, and the Asia-Pacific regions, with maximum revenue generated from the USA.
49GF Score

Get the complete analysis for STU:7OC0

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.34
Price
€0.81
GF Value